Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine

Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine

OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age for chronic migraine control. However, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Damiana Scuteri, Paolo Tonin, Pierluigi Nicotera, Marilù Vulnera, Giuseppina Cristina Altieri, Assunta Tarsitano, Giacinto Bagetta, Maria Tiziana Corasaniti
Formato: Artículo
Lenguaje:English
Publicado: MDPI AG 2022-08-01
Colección:Toxins
Materias:
onabotulinumtoxinA
migraine
anti-CGRP monoclonal antibodies
PRISMA 2020
pooled analysis
Acceso en línea:https://www.mdpi.com/2072-6651/14/8/529

Internet

https://www.mdpi.com/2072-6651/14/8/529

Ejemplares similares